ixekizumab vs vunakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline

ixekizumab · Taltz

Marketed by Eli Lilly and partners

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT01695239 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.

Next expected readout: February 2028 · NCT07443956 (registry estimate)

Reported efficacy

Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) (Week 24): ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 (met)

Result source: NCT02349295

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriatic Arthritismonoclonal antibody
Partial signal

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Proportion of subjects achieving ACR 20 improvement at week 12: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively (met)

Result source: NCT05055934

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointixekizumabvunakizumab
ACR2053.3% vs 19.5%+33.8 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
7 other results
  • 48% vs 19.5% 80 mg Q2W · wk 24 · n 123 · Phase 3 · primary NCT02349295
  • 57.9% vs 30.2% Q4W · wk 24 · n 107 · Phase 3 · primary NCT01695239
  • 62.1% vs 30.2% Q2W · wk 24 · n 103 · Phase 3 · primary NCT01695239
  • 50% vs 22% 80 mg Q4W · wk 12 · n 122 · Phase 3 · secondary NCT02349295
  • 48% vs 22% 80 mg Q2W · wk 12 · n 123 · Phase 3 · secondary NCT02349295
  • 57% vs 31.1% Q4W · wk 12 · n 107 · Phase 3 · secondary NCT01695239
  • 60.2% vs 31.1% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01695239
—Trial running · NCT06640257
ACR5035.2% vs 5.1%+30.1 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
4 other results
  • 33.3% vs 5.1% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • 40.2% vs 15.1% Q4W · wk 24 · n 107 · Phase 3 · secondary NCT01695239
  • 46.6% vs 15.1% Q2W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • 50.5% vs 46.6% wk 24 · n 283 · Phase 4 · secondary NCT03151551
—Trial running · NCT06640257
PASI 7557.4% vs 10.4%+47 vs placebo80 mg Q4W · wk 12 · n 68NCT02349295
1 other result
  • 61.8% vs 10.4% 80 mg Q2W · wk 12 · n 68 · Phase 3 · secondary NCT02349295
—Trial running · NCT06640257
Minimal disease activity27.9% vs 3.4%+24.5 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
1 other result
  • 23.6% vs 3.4% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
—Trial running · NCT06640257
HAQ-DI, change-0.6 vs -0.2−0.4 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
5 other results
  • -0.4 vs -0.2 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • -0.4 vs -0.2 Q4W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • -0.5 vs -0.2 Q2W · wk 24 · n 98 · Phase 3 · secondary NCT01695239
  • -0.8 vs -0.7 n 51 · Phase 3 · secondary NCT02584855
  • -0.7 vs -0.6 wk 52 · n 242 · Phase 4 · secondary NCT03151551
—Trial running · NCT06640257

ACR20

ixekizumab
53.3% vs 19.5%+33.8 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
7 other results
  • 48% vs 19.5% 80 mg Q2W · wk 24 · n 123 · Phase 3 · primary NCT02349295
  • 57.9% vs 30.2% Q4W · wk 24 · n 107 · Phase 3 · primary NCT01695239
  • 62.1% vs 30.2% Q2W · wk 24 · n 103 · Phase 3 · primary NCT01695239
  • 50% vs 22% 80 mg Q4W · wk 12 · n 122 · Phase 3 · secondary NCT02349295
  • 48% vs 22% 80 mg Q2W · wk 12 · n 123 · Phase 3 · secondary NCT02349295
  • 57% vs 31.1% Q4W · wk 12 · n 107 · Phase 3 · secondary NCT01695239
  • 60.2% vs 31.1% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01695239
vunakizumab
—Trial running · NCT06640257

ACR50

ixekizumab
35.2% vs 5.1%+30.1 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
4 other results
  • 33.3% vs 5.1% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • 40.2% vs 15.1% Q4W · wk 24 · n 107 · Phase 3 · secondary NCT01695239
  • 46.6% vs 15.1% Q2W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • 50.5% vs 46.6% wk 24 · n 283 · Phase 4 · secondary NCT03151551
vunakizumab
—Trial running · NCT06640257

PASI 75

ixekizumab
57.4% vs 10.4%+47 vs placebo80 mg Q4W · wk 12 · n 68NCT02349295
1 other result
  • 61.8% vs 10.4% 80 mg Q2W · wk 12 · n 68 · Phase 3 · secondary NCT02349295
vunakizumab
—Trial running · NCT06640257

Minimal disease activity

ixekizumab
27.9% vs 3.4%+24.5 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
1 other result
  • 23.6% vs 3.4% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
vunakizumab
—Trial running · NCT06640257

HAQ-DI, change

ixekizumab
-0.6 vs -0.2−0.4 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
5 other results
  • -0.4 vs -0.2 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • -0.4 vs -0.2 Q4W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • -0.5 vs -0.2 Q2W · wk 24 · n 98 · Phase 3 · secondary NCT01695239
  • -0.8 vs -0.7 n 51 · Phase 3 · secondary NCT02584855
  • -0.7 vs -0.6 wk 52 · n 242 · Phase 4 · secondary NCT03151551
vunakizumab
—Trial running · NCT06640257
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively NCT05055934 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ixekizumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricixekizumab
Dropout rate
—Q2Wa
NCT01695239 · Phase 3
show 22 more results
—Q4W
NCT01695239 · Phase 3
6.8%Q2W
NCT01695239 · Phase 3
9.3%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
9%80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
11.4%80 mg Q2W
NCT02349295 · Phase 3
6%Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
6%Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
6.4%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
—Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
26.1%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—Q2Wa
NCT01695239 · Phase 3
show 22 more results
—Q4W
NCT01695239 · Phase 3
2.9%Q2W
NCT01695239 · Phase 3
1.9%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
4.1%80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
5.7%80 mg Q2W
NCT02349295 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
—Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
3.6%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
Serious AEs
0%Q2Wa
NCT01695239 · Phase 3
show 22 more results
0%Q4W
NCT01695239 · Phase 3
10.4%Q2W
NCT01695239 · Phase 3
15%Q4W
NCT01695239 · Phase 3
5.6%Q2W
NCT01695239 · Phase 3
2.9%Q4W
NCT01695239 · Phase 3
0%80 mg Q4W
NCT02349295 · Phase 3
11.7%80 mg Q4W
NCT02349295 · Phase 3
2.5%80 mg Q4W
NCT02349295 · Phase 3
0%80 mg Q2W
NCT02349295 · Phase 3
9.3%80 mg Q2W
NCT02349295 · Phase 3
6.5%80 mg Q2W
NCT02349295 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
0.5%Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
4.2%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
2.6%Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
4.5%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1.1%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1.3%Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
5.1%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
Q2Wa
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
show 20 more results
Q4W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q2W
viral upper respiratory tract infection 11.5% (placebo 4.7%)
upper respiratory tract infection 9.8% (placebo 6.6%)
injection site reaction 7.1% (placebo 0%)
NCT01695239 · Phase 3
Q4W
upper respiratory tract infection 11.2% (placebo 6.6%)
viral upper respiratory tract infection 11.2% (placebo 4.7%)
injection site reaction 6.4% (placebo 0%)
NCT01695239 · Phase 3
Q2W
injection site reaction 12.1% (placebo 0%)
injection site erythema 6.5% (placebo 0%)
viral upper respiratory tract infection 5.6% (placebo 4.7%)
NCT01695239 · Phase 3
Q4W
injection site reaction 15.7% (placebo 0%)
injection site erythema 12.7% (placebo 0%)
bronchitis 2.9% (placebo 2.8%)
NCT01695239 · Phase 3
80 mg Q4W
ear infection 6.7% (placebo 0.8%)
goitre 6.7% (placebo 0%)
hepatic steatosis 6.7% (placebo 0.8%)
NCT02349295 · Phase 3
80 mg Q4W
nasopharyngitis 18% (placebo 3.4%)
upper respiratory tract infection 13.5% (placebo 7.6%)
bronchitis 9.9% (placebo 3.4%)
NCT02349295 · Phase 3
80 mg Q4W
upper respiratory tract infection 9.8% (placebo 7.6%)
nasopharyngitis 7.4% (placebo 3.4%)
oropharyngeal pain 5.7% (placebo 0%)
NCT02349295 · Phase 3
80 mg Q2W
injection site pain 11.8% (placebo 1.7%)
injection site reaction 11.8% (placebo 0.8%)
vulvovaginal candidiasis 8.3% (placebo 0%)
NCT02349295 · Phase 3
80 mg Q2W
upper respiratory tract infection 18.7% (placebo 7.6%)
nasopharyngitis 14% (placebo 3.4%)
bronchitis 10.3% (placebo 3.4%)
NCT02349295 · Phase 3
80 mg Q2W
injection site reaction 12.2% (placebo 0.8%)
upper respiratory tract infection 9.8% (placebo 7.6%)
hypertension 4.9% (placebo 2.5%)
NCT02349295 · Phase 3
Q2W/Q4W
latent tuberculosis 8.6%
pyrexia 8.6%
injection site erythema 1.9%
NCT05855967 · Phase 4 · registry result, not featured evidence
Q4W
latent tuberculosis 9.8%
urinary tract infection 4.9%
c-reactive protein increased 2.4%
NCT05855967 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13.4%
upper respiratory tract infection 6.4%
injection site reaction 5.7%
NCT03151551 · Phase 4 · registry result, not featured evidence
nasopharyngitis 1.9%
upper respiratory tract infection 1.1%
injection site reaction 0%
NCT03151551 · Phase 4 · registry result, not featured evidence
80 mg every 2 weeks
nasopharyngitis 14.3% (placebo 5.1%)
upper respiratory tract infection 9% (placebo 5.1%)
bronchitis 3.8% (placebo 1.3%)
NCT02584855 · Phase 3 · registry result, not featured evidence
80 mg every 2 weeks
upper respiratory tract infection 2.3% (placebo 5.1%)
psoriasis 1.1% (placebo 5.1%)
alanine aminotransferase increased 0.8% (placebo 1.3%)
NCT02584855 · Phase 3 · registry result, not featured evidence
80 mg every 2 weeks
nasopharyngitis 13.4% (placebo 5.1%)
upper respiratory tract infection 9.3% (placebo 5.1%)
injection site reaction 7.2% (placebo 0%)
NCT02584855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.9% (placebo 5.1%)
upper respiratory tract infection 11.4% (placebo 5.1%)
uterine leiomyoma 6.3% (placebo 0%)
NCT02584855 · Phase 3 · registry result, not featured evidence
injection site reaction 15% (placebo 0%)
upper respiratory tract infection 12.4% (placebo 5.1%)
nasopharyngitis 8.6% (placebo 5.1%)
NCT02584855 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ixekizumab

ACR20 53.3% (n=122) vs 19.5% (n=118) placebo @ 24wk80 mg Q4W
responder rate · % of participants
NCT02349295 · Phase 3
show 7 more results
50% (n=122) vs 22% (n=118) placebo @ 12wk80 mg Q4W
NCT02349295 · Phase 3
48% (n=123) vs 19.5% (n=118) placebo @ 24wk80 mg Q2W
NCT02349295 · Phase 3
48% (n=123) vs 22% (n=118) placebo @ 12wk80 mg Q2W
NCT02349295 · Phase 3
57.9% (n=107) vs 30.2% (n=106) placebo @ 24wkQ4W
NCT01695239 · Phase 3
62.1% (n=103) vs 30.2% (n=106) placebo @ 24wkQ2W
NCT01695239 · Phase 3
57% (n=107) vs 31.1% (n=106) placebo @ 12wkQ4W
NCT01695239 · Phase 3
60.2% (n=103) vs 31.1% (n=106) placebo @ 12wkQ2W
NCT01695239 · Phase 3
ACR50 35.2% (n=122) vs 5.1% (n=118) placebo @ 24wk80 mg Q4W
responder rate · % of participants
NCT02349295 · Phase 3
show 4 more results
33.3% (n=123) vs 5.1% (n=118) placebo @ 24wk80 mg Q2W
NCT02349295 · Phase 3
40.2% (n=107) vs 15.1% (n=106) placebo @ 24wkQ4W
NCT01695239 · Phase 3
46.6% (n=103) vs 15.1% (n=106) placebo @ 24wkQ2W
NCT01695239 · Phase 3
50.5% (n=283) vs 46.6% (n=283) Adalimumab @ 24wk
NCT03151551 · Phase 4 · registry result, not featured evidence
ACR70 22.1% (n=122) vs 0% (n=118) placebo @ 24wk80 mg Q4W
responder rate · % of participants
NCT02349295 · Phase 3
show 3 more results
12.2% (n=123) vs 0% (n=118) placebo @ 24wk80 mg Q2W
NCT02349295 · Phase 3
23.4% (n=107) vs 5.7% (n=106) placebo @ 24wkQ4W
NCT01695239 · Phase 3
34% (n=103) vs 5.7% (n=106) placebo @ 24wkQ2W
NCT01695239 · Phase 3
HAQ-DI -0.6 vs -0.2 placebo score @ 24wk80 mg Q4W
absolute change · score
NCT02349295 · Phase 3
show 5 more results
-0.4 vs -0.2 placebo score @ 24wk80 mg Q2W
NCT02349295 · Phase 3
-0.4431 vs -0.1797 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-0.4963 vs -0.1797 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-0.68 vs -0.62 Adalimumab score @ 52wk
NCT03151551 · Phase 4 · registry result, not featured evidence
-0.79 vs -0.67 placebo score
NCT02584855 · Phase 3 · registry result, not featured evidence
Modified Sharp 0.17 vs 0.49 placebo score @ 24wkQ4W
absolute change · score
NCT01695239 · Phase 3
show 1 more result
0.08 vs 0.49 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
PASI 75 75.3% (n=73) vs 7.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 75
NCT01695239 · Phase 3
show 3 more results
69.5% (n=59) vs 7.5% (n=67) placebo @ 12wkQ2W
PASI 75
NCT01695239 · Phase 3
71.2% (n=60) vs 10.9% (n=38) placebo @ 24wkQ4W
PASI 75
NCT01695239 · Phase 3
80.4% (n=49) vs 10.9% (n=38) placebo @ 24wkQ2W
PASI 75
NCT01695239 · Phase 3
PASI 90 52.1% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 90
NCT01695239 · Phase 3
show 3 more results
57.6% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2W
PASI 90
NCT01695239 · Phase 3
56.2% (n=60) vs 6.3% (n=38) placebo @ 24wkQ4W
PASI 90
NCT01695239 · Phase 3
67.9% (n=49) vs 6.3% (n=38) placebo @ 24wkQ2W
PASI 90
NCT01695239 · Phase 3
PASI 100 31.5% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 100
NCT01695239 · Phase 3
show 3 more results
40.7% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2W
PASI 100
NCT01695239 · Phase 3
42.5% (n=60) vs 3.1% (n=38) placebo @ 24wkQ4W
PASI 100
NCT01695239 · Phase 3
53.6% (n=49) vs 3.1% (n=38) placebo @ 24wkQ2W
PASI 100
NCT01695239 · Phase 3
Enthesitis -0.9 vs -0.8 placebo score @ 12wkQ4W
absolute change · score
NCT01695239 · Phase 3
show 3 more results
-1.5 vs -0.8 placebo score @ 12wkQ2W
NCT01695239 · Phase 3
-1.3 vs -0.8 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-1.4 vs -0.8 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
Itch NRS -3.4 vs -0.7 placebo score @ 12wk80 mg Q4W
absolute change · score
NCT02349295 · Phase 3
show 6 more results
-3.3 vs -0.7 placebo score @ 12wk80 mg Q2W
NCT02349295 · Phase 3
-2.6 vs 0.2 placebo score @ 12wkQ4W
NCT01695239 · Phase 3
-2.8 vs 0.2 placebo score @ 12wkQ2W
NCT01695239 · Phase 3
-2.9 vs -0.3 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-2.8 vs -0.3 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-3.83 vs -3.54 Adalimumab score @ 52wk
NCT03151551 · Phase 4 · registry result, not featured evidence
Fatigue NRS -2 vs -0.7 placebo score @ 24wk80 mg Q4W
absolute change · score
NCT02349295 · Phase 3
show 4 more results
-2.1 vs -0.7 placebo score @ 24wk80 mg Q2W
NCT02349295 · Phase 3
-1.6 vs -1.3 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-1.9 vs -1.3 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-3.03 vs -2.95 Adalimumab score @ 52wk
NCT03151551 · Phase 4 · registry result, not featured evidence
SF-36 PCS 7.45 vs 2.94 placebo score @ 24wkQ4W
absolute change · score
PCS Score
NCT01695239 · Phase 3
show 1 more result
8.24 vs 2.94 placebo score @ 24wkQ2W
PCS Score
NCT01695239 · Phase 3

+ 45 further endpoints in the CSV export.

Psoriasis

Shared mechanism: IL-17 · full Psoriasis pipeline

ixekizumab · Taltz

Marketed by Eli Lilly and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01474512 · Phase 3 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.

Next expected readout: December 2027 · NCT04537689 (registry estimate)

Reported efficacy

Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20]): ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. (met)

Result source: NCT01695239

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT04839016 · Phase 3 · status unknown

This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025).

Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.

Next expected readout: March 2027 · NCT06779097 (registry estimate)

Reported efficacy

Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). (met)

Result source: NCT04839016

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointixekizumabvunakizumab
PASI 7584.2% vs 7.3%+76.9 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 87.3% vs 7.3% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 87.4% vs 8% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 93.8% vs 8% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 82.6% vs 3.9% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 89.1% vs 3.9% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 77.5% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 89.7% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 88.7% vs 25% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 53.9% vs 8.9% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 84.2% vs 26.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 88.2% vs 68.7% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 82.1% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 82.8% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · primary NCT01107457
  • 76.7% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · primary NCT01107457
  • 28.6% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 22.9% vs 5.1% wk 2 · n 520 · Phase 4 · secondary NCT03573323
—Trial running · NCT06833307
PASI 9072.8% vs 42.2%vs Ustekinumabwk 12 · n 136NCT02561806
9 other results
  • 65.3% vs 3.1% 80 mg every 4 weeks · wk 12 · n 386 · Phase 3 · secondary NCT01646177
  • 68.1% vs 3.1% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 75.9% vs 2.3% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 82.4% vs 2.3% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 59.7% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 70.7% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 78.3% vs 5.4% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 58.5% vs 35.9% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 21% vs 7.9% wk 4 · n 520 · Phase 4 · secondary NCT03573323
—Trial running · NCT06833307
PASI 10035% vs 0%+35 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
10 other results
  • 37.7% vs 0% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 29.3% vs 0% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 33% vs 0% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 30.8% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 40.5% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 49.6% vs 1.8% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 36% vs 14.5% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 41.3% vs 24.9% wk 12 · n 520 · Phase 4 · primary NCT03573323
  • 29.6% vs 13.6% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 6.7% vs 1.4% wk 4 · n 520 · Phase 4 · secondary NCT03573323
—Trial running · NCT06833307
sPGA 0/175.4% vs 6.7%+68.7 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 80.5% vs 6.7% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 79.9% vs 3.4% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 86.4% vs 3.4% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 76.4% vs 3.2% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 81.8% vs 3.2% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 72.9% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 83.2% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 80.9% vs 10.7% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 73.3% vs 2.7% 80mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT02718898
  • 47.8% vs 7.1% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 76.3% vs 5.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 83.6% vs 57.2% wk 12 · n 134 · Phase 3 · secondary NCT02561806
  • 71.4% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
  • 72.4% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · secondary NCT01107457
  • 70% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · secondary NCT01107457
  • 25% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
—Trial running · NCT06833307
DLQI, change-9.6 vs -1.7−7.9 vs placebo80 mg every 4 weeks · wk 12 · n 375NCT01646177
12 other results
  • -10.2 vs -1.7 80 mg every 2 weeks · wk 12 · n 377 · Phase 3 · secondary NCT01646177
  • -8.6 vs 0.9 80 mg Q4W · wk 12 · n 170 · Phase 3 · secondary NCT03364309
  • -8.9 vs 0.9 80 mg Q2W · wk 12 · n 175 · Phase 3 · secondary NCT03364309
  • -10.7 vs -1 Q4W · wk 12 · n 421 · Phase 3 · secondary NCT01474512
  • -11.1 vs -1 Q2W · wk 12 · n 427 · Phase 3 · secondary NCT01474512
  • -9.4 vs -2 Q4W · wk 12 · n 338 · Phase 3 · secondary NCT01597245
  • -10.4 vs -2 Q2W · wk 12 · n 343 · Phase 3 · secondary NCT01597245
  • -9.7 vs -1.4 Q2W · wk 12 · n 74 · Phase 3 · secondary NCT02718898
  • -8.2 vs -1.2 150 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
  • -8.4 vs -1.2 75 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.6 vs -1.2 25 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.3 vs -1.2 10 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
—Trial running · NCT06833307

PASI 75

ixekizumab
84.2% vs 7.3%+76.9 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 87.3% vs 7.3% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 87.4% vs 8% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 93.8% vs 8% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 82.6% vs 3.9% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 89.1% vs 3.9% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 77.5% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 89.7% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 88.7% vs 25% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 53.9% vs 8.9% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 84.2% vs 26.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 88.2% vs 68.7% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 82.1% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 82.8% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · primary NCT01107457
  • 76.7% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · primary NCT01107457
  • 28.6% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 22.9% vs 5.1% wk 2 · n 520 · Phase 4 · secondary NCT03573323
vunakizumab
—Trial running · NCT06833307

PASI 90

ixekizumab
72.8% vs 42.2%vs Ustekinumabwk 12 · n 136NCT02561806
9 other results
  • 65.3% vs 3.1% 80 mg every 4 weeks · wk 12 · n 386 · Phase 3 · secondary NCT01646177
  • 68.1% vs 3.1% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 75.9% vs 2.3% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 82.4% vs 2.3% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 59.7% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 70.7% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 78.3% vs 5.4% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 58.5% vs 35.9% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 21% vs 7.9% wk 4 · n 520 · Phase 4 · secondary NCT03573323
vunakizumab
—Trial running · NCT06833307

PASI 100

ixekizumab
35% vs 0%+35 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
10 other results
  • 37.7% vs 0% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 29.3% vs 0% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 33% vs 0% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 30.8% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 40.5% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 49.6% vs 1.8% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 36% vs 14.5% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 41.3% vs 24.9% wk 12 · n 520 · Phase 4 · primary NCT03573323
  • 29.6% vs 13.6% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 6.7% vs 1.4% wk 4 · n 520 · Phase 4 · secondary NCT03573323
vunakizumab
—Trial running · NCT06833307

sPGA 0/1

ixekizumab
75.4% vs 6.7%+68.7 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 80.5% vs 6.7% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 79.9% vs 3.4% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 86.4% vs 3.4% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 76.4% vs 3.2% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 81.8% vs 3.2% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 72.9% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 83.2% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 80.9% vs 10.7% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 73.3% vs 2.7% 80mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT02718898
  • 47.8% vs 7.1% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 76.3% vs 5.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 83.6% vs 57.2% wk 12 · n 134 · Phase 3 · secondary NCT02561806
  • 71.4% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
  • 72.4% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · secondary NCT01107457
  • 70% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · secondary NCT01107457
  • 25% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
vunakizumab
—Trial running · NCT06833307

DLQI, change

ixekizumab
-9.6 vs -1.7−7.9 vs placebo80 mg every 4 weeks · wk 12 · n 375NCT01646177
12 other results
  • -10.2 vs -1.7 80 mg every 2 weeks · wk 12 · n 377 · Phase 3 · secondary NCT01646177
  • -8.6 vs 0.9 80 mg Q4W · wk 12 · n 170 · Phase 3 · secondary NCT03364309
  • -8.9 vs 0.9 80 mg Q2W · wk 12 · n 175 · Phase 3 · secondary NCT03364309
  • -10.7 vs -1 Q4W · wk 12 · n 421 · Phase 3 · secondary NCT01474512
  • -11.1 vs -1 Q2W · wk 12 · n 427 · Phase 3 · secondary NCT01474512
  • -9.4 vs -2 Q4W · wk 12 · n 338 · Phase 3 · secondary NCT01597245
  • -10.4 vs -2 Q2W · wk 12 · n 343 · Phase 3 · secondary NCT01597245
  • -9.7 vs -1.4 Q2W · wk 12 · n 74 · Phase 3 · secondary NCT02718898
  • -8.2 vs -1.2 150 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
  • -8.4 vs -1.2 75 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.6 vs -1.2 25 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.3 vs -1.2 10 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
vunakizumab
—Trial running · NCT06833307
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). NCT04839016 · Phase 3 · design grade: strong · publication or press release
PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all NCT03463187 · Phase 1/2 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ixekizumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricixekizumab
Dropout rate
—Ixe Long-Term Extensiona
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
4.2%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
5.6%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
2.6%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
5.5%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0.9%IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
—IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
—IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
—PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
6.8%Q2W
NCT01695239 · Phase 3
9.3%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
5.7%80 mg every 2 weeks
NCT01646177 · Phase 3
6.7%80 mg every 4 weeks
NCT01646177 · Phase 3
6%Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
6%Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
20%Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
14.3%Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
10.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.3%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
7.4%Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
3.7%Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
1.1%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
12.1%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
11.6%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
12.4%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
7.8%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
5.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
3.6%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
10.3%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
25%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
—80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Ixe Long-Term Extensiona
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
2.3%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
2.3%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.1%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.4%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
—IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
—IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
—PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
2.9%Q2W
NCT01695239 · Phase 3
1.9%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
2.1%80 mg every 2 weeks
NCT01646177 · Phase 3
2.3%80 mg every 4 weeks
NCT01646177 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
20%Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
0%Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
2.9%
NCT03573323 · Phase 4 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
3.7%Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
1.5%Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
1.1%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
2.8%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
1.6%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
4.2%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
1%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
2%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
7.1%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
—80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
12.7%Ixe Long-Term Extensiona
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
1.6%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
2.8%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
3.2%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
10.3%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.8%Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
6.1%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
3.8%Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
6.1%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.8%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
12.5%Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.5%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
10.9%Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.4%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
4.1%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
2.3%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
5.3%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
8.4%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
3.6%ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
0%ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0.9%IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
8.8%IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
6.2%IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
2.9%IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
0%IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
5.7%PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
0%PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0%Q2W
NCT01695239 · Phase 3
0%Q4W
NCT01695239 · Phase 3
10.4%Q2W
NCT01695239 · Phase 3
15%Q4W
NCT01695239 · Phase 3
5.6%Q2W
NCT01695239 · Phase 3
2.9%Q4W
NCT01695239 · Phase 3
2.3%80 mg every 2 weeks
NCT01646177 · Phase 3
1.6%80 mg every 4 weeks
NCT01646177 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
0.5%Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
—Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
3.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
4.3%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
2%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
2%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
4.4%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
5.4%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.1%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.3%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
1.9%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
1.1%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
6.3%Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
1.9%Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
1.5%Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
5.3%Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
0%Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
4.4%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
11.3%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.3%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.2%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
20%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.2%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
4.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
3.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
2.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.6%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
7.1%80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
nasopharyngitis 16.9% (placebo 11.5%)
upper respiratory tract infection 8.4% (placebo 8%)
arthralgia 5.1% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 79 more results
Q2W
nasopharyngitis 11.3% (placebo 11.5%)
injection site reaction 9.7% (placebo 0.9%)
injection site erythema 6.5% (placebo 0%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 10.4% (placebo 11.5%)
injection site reaction 6.3% (placebo 0.9%)
upper respiratory tract infection 4.6% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 10.6% (placebo 11.5%)
upper respiratory tract infection 5.2% (placebo 8%)
injection site reaction 3.7% (placebo 0.9%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 24.4% (placebo 11.5%)
arthralgia 10.3% (placebo 2.7%)
upper respiratory tract infection 10.3% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q12W
nasopharyngitis 18.1% (placebo 11.5%)
upper respiratory tract infection 8.8% (placebo 8%)
headache 7% (placebo 2.2%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 22.3% (placebo 11.5%)
upper respiratory tract infection 7.9% (placebo 8%)
arthralgia 5.7% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
nasopharyngitis 15.4% (placebo 11.5%)
influenza 7.7% (placebo 1.8%)
upper respiratory tract infection 7.7% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 19.7% (placebo 11.5%)
upper respiratory tract infection 13.6% (placebo 8%)
injection site reaction 9.2% (placebo 0.9%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 17.7% (placebo 11.5%)
back pain 9.7% (placebo 3.1%)
upper respiratory tract infection 6.5% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
nasopharyngitis 16.6% (placebo 11.5%)
upper respiratory tract infection 8.3% (placebo 8%)
arthralgia 5% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 17.5% (placebo 14.4%)
upper respiratory tract infection 10.5% (placebo 6.1%)
injection site reaction 10% (placebo 0.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
nasopharyngitis 12.8% (placebo 14.4%)
upper respiratory tract infection 11% (placebo 6.1%)
arthralgia 4.9% (placebo 6.1%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q2W
injection site reaction 11.4% (placebo 0.8%)
nasopharyngitis 9.7% (placebo 14.4%)
upper respiratory tract infection 5.7% (placebo 6.1%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 16.3% (placebo 14.4%)
upper respiratory tract infection 14.3% (placebo 6.1%)
headache 8.2% (placebo 3.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 8.1% (placebo 14.4%)
injection site reaction 5.5% (placebo 0.8%)
headache 4.9% (placebo 3.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 16% (placebo 14.4%)
upper respiratory tract infection 9.3% (placebo 6.1%)
vulvovaginal candidiasis 9.1% (placebo 0%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 18.7% (placebo 14.4%)
upper respiratory tract infection 12.9% (placebo 6.1%)
injection site reaction 6.5% (placebo 0.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
nasopharyngitis 14.3% (placebo 7.1%)
pharyngitis 14.3% (placebo 0%)
tonsillitis 14.3% (placebo 3.6%)
NCT03073200 · Phase 3
acne 11.1% (placebo 1.8%)
headache 11.1% (placebo 1.8%)
influenza 11.1% (placebo 0%)
NCT03073200 · Phase 3
nasopharyngitis 11.3% (placebo 7.1%)
headache 10.4% (placebo 1.8%)
injection site reaction 9.6% (placebo 0%)
NCT03073200 · Phase 3
nasopharyngitis 32.4% (placebo 7.1%)
tonsillitis 8.8% (placebo 3.6%)
viral upper respiratory tract infection 8.8% (placebo 0%)
NCT03073200 · Phase 3
injection site reaction 17.7% (placebo 0%)
nasopharyngitis 14.2% (placebo 7.1%)
upper respiratory tract infection 11.5% (placebo 7.1%)
NCT03073200 · Phase 3
upper respiratory tract infection 16.2% (placebo 7.1%)
nasopharyngitis 11.8% (placebo 7.1%)
headache 8.8% (placebo 1.8%)
NCT03073200 · Phase 3
diarrhoea 6.1% (placebo 1.8%)
nasopharyngitis 6.1% (placebo 7.1%)
pharyngitis 6.1% (placebo 0%)
NCT03073200 · Phase 3
injection site reaction 15.1% (placebo 0%)
nasopharyngitis 13.2% (placebo 7.1%)
upper respiratory tract infection 9.4% (placebo 7.1%)
NCT03073200 · Phase 3
upper respiratory tract infection 29.4% (placebo 7.1%)
bronchitis 8.8% (placebo 0%)
pharyngitis 8.8% (placebo 0%)
NCT03073200 · Phase 3
Q2W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q4W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q2W
viral upper respiratory tract infection 11.5% (placebo 4.7%)
upper respiratory tract infection 9.8% (placebo 6.6%)
injection site reaction 7.1% (placebo 0%)
NCT01695239 · Phase 3
Q4W
upper respiratory tract infection 11.2% (placebo 6.6%)
viral upper respiratory tract infection 11.2% (placebo 4.7%)
injection site reaction 6.4% (placebo 0%)
NCT01695239 · Phase 3
Q2W
injection site reaction 12.1% (placebo 0%)
injection site erythema 6.5% (placebo 0%)
viral upper respiratory tract infection 5.6% (placebo 4.7%)
NCT01695239 · Phase 3
Q4W
injection site reaction 15.7% (placebo 0%)
injection site erythema 12.7% (placebo 0%)
bronchitis 2.9% (placebo 2.8%)
NCT01695239 · Phase 3
80 mg every 2 weeks
injection site reaction 9.6% (placebo 1.6%)
nasopharyngitis 6.8% (placebo 5.7%)
headache 4.2% (placebo 2.6%)
NCT01646177 · Phase 3
80 mg every 4 weeks
injection site reaction 11.3% (placebo 1.6%)
nasopharyngitis 7.6% (placebo 5.7%)
headache 4.2% (placebo 2.6%)
NCT01646177 · Phase 3
Q2W/Q4W
latent tuberculosis 8.6%
pyrexia 8.6%
injection site erythema 1.9%
NCT05855967 · Phase 4 · registry result, not featured evidence
Q4W
latent tuberculosis 9.8%
urinary tract infection 4.9%
c-reactive protein increased 2.4%
NCT05855967 · Phase 4 · registry result, not featured evidence
injection site reaction 9.4%
upper respiratory tract infection 7.7%
nasopharyngitis 6.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
80 mg Q2W
blood glucose increased 17.4% (placebo 6.3%)
folliculitis 13% (placebo 5.1%)
hepatic function abnormal 13% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 31% (placebo 27.8%)
injection site reaction 17% (placebo 10.1%)
tinea pedis 10% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 12% (placebo 27.8%)
oropharyngeal pain 10% (placebo 2.5%)
blood triglycerides increased 8% (placebo 0%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
alopecia 10% (placebo 0%)
blood immunoglobulin a increased 10% (placebo 1.3%)
blood urine present 10% (placebo 6.3%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 20% (placebo 27.8%)
injection site reaction 11.1% (placebo 10.1%)
oropharyngeal pain 11.1% (placebo 2.5%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
alopecia 0% (placebo 0%)
arthralgia 0% (placebo 0%)
blood glucose decreased 0% (placebo 0%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 15.9% (placebo 27.8%)
injection site reaction 10.8% (placebo 10.1%)
urticaria 5.7% (placebo 11.4%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 25.8% (placebo 27.8%)
blood urine present 12.9% (placebo 6.3%)
tinea pedis 12.9% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 27.2% (placebo 27.8%)
injection site reaction 18.5% (placebo 10.1%)
tinea pedis 12% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.9% (placebo 27.8%)
oropharyngeal pain 8.5% (placebo 2.5%)
pruritus 8.5% (placebo 2.5%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
tonsillitis 28.6% (placebo 0%)
upper respiratory tract infection 28.6% (placebo 27.8%)
dermatitis allergic 14.3% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 16.3% (placebo 27.8%)
injection site reaction 7% (placebo 10.1%)
rhinitis 7% (placebo 1.3%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
hepatic function abnormal 1.3% (placebo 5.1%)
blood glucose increased 1.1% (placebo 6.3%)
upper respiratory tract infection 1.1% (placebo 27.8%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.4% (placebo 27.8%)
injection site reaction 7.5% (placebo 10.1%)
hepatic function abnormal 5.7% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 16% (placebo 6.8%)
injection site reaction 6.7% (placebo 0%)
headache 4% (placebo 5.4%)
NCT02718898 · Phase 3 · registry result, not featured evidence
nasopharyngitis 37.5%
back pain 6.3%
bronchitis 4.2%
NCT02634801 · Phase 3 · registry result, not featured evidence
nasopharyngitis 37%
headache 13%
injection site reaction 13%
NCT02634801 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17%
injection site erythema 7.4%
headache 5.2%
NCT02561806 · Phase 3 · registry result, not featured evidence
nasopharyngitis 27.5%
headache 7.6%
arthralgia 6.1%
NCT02561806 · Phase 3 · registry result, not featured evidence
arthralgia 0%
back pain 0%
headache 0%
NCT02561806 · Phase 3 · registry result, not featured evidence
80 mg
viral upper respiratory tract infection 39.6%
eczema 12.1%
injection site reaction 8.8%
NCT01624233 · Phase 3 · registry result, not featured evidence
80 mg
viral upper respiratory tract infection 20%
eczema 12.5%
eczema asteatotic 11.3%
NCT01624233 · Phase 3 · registry result, not featured evidence
80 mg Q2W
viral upper respiratory tract infection 12%
upper respiratory tract infection 11.3%
injection site reaction 8%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q2W
viral upper respiratory tract infection 37.5%
vaginal infection 25%
injection site erythema 12.5%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 22.2%
alanine aminotransferase increased 11.1%
aspartate aminotransferase increased 11.1%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W/Q2W
viral upper respiratory tract infection 17.3%
upper respiratory tract infection 12.7%
headache 5.2%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W/Q2W
arthralgia 20%
benign bone neoplasm 20%
blood glucose increased 20%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.8%
viral upper respiratory tract infection 13.2%
injection site reaction 5.8%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 33.3%
biopsy breast 16.7%
influenza 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
Q2W
arthralgia 33.3%
acne 16.7%
hyperhidrosis 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
Q4W
biopsy prostate 33.3%
injection site urticaria 33.3%
hordeolum 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
80 mg
upper respiratory tract infection 8.6%
injection site reaction 4.3%
NCT01777191 · Phase 3 · registry result, not featured evidence
80 mg
injection site reaction 4.9%
upper respiratory tract infection 4.9%
NCT01777191 · Phase 3 · registry result, not featured evidence
80 mg
injection site reaction 7.8%
upper respiratory tract infection 3.9%
NCT01777191 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 14.3% (placebo 18.5%)
dermatitis contact 7.1% (placebo 0%)
dry skin 7.1% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 10.3% (placebo 18.5%)
cough 6.9% (placebo 0%)
dizziness 6.9% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
25 mg
headache 13.3% (placebo 3.7%)
injection site reaction 10% (placebo 0%)
nasopharyngitis 10% (placebo 18.5%)
NCT01107457 · Phase 2 · registry result, not featured evidence
10 mg
headache 14.3% (placebo 3.7%)
nasopharyngitis 10.7% (placebo 18.5%)
dizziness 7.1% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
80mg Q2W Multiple Dose
pruritus 42.9%
upper respiratory tract infection 35.7%
diarrhoea 21.4%
NCT03073213 · Phase 1 · registry result, not featured evidence
80mg Q4W Multiple Dose
upper respiratory tract infection 20%
arthralgia 13.3%
diarrhoea 13.3%
NCT03073213 · Phase 1 · registry result, not featured evidence
Single Dose
pruritus 41.7%
protein urine present 33.3%
flatulence 25%
NCT03073213 · Phase 1 · registry result, not featured evidence
alopecia 3.7%
arthralgia 3.7%
back pain 3.7%
NCT02993471 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 76 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ixekizumab

sPGA 0/1 75.4% (n=386) vs 6.7% (n=193) placebo @ 12wk80 mg every 4 weeks
responder rate · % of participants
NCT01646177 · Phase 3 · converted to % from 291 Participants as posted
show 21 more results
80.5% (n=385) vs 6.7% (n=193) placebo @ 12wk*80 mg every 2 weeks
NCT01646177 · Phase 3 · converted to % from 310 Participants as posted
79.9% (n=174) vs 3.4% (n=88) placebo @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
86.4% (n=176) vs 3.4% (n=88) placebo @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
73.3% (n=75) vs 2.7% (n=74) placebo @ 12wk*80mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
71.4% (n=28) vs 7.7% (n=26) placebo @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
72.4% (n=29) vs 7.7% (n=26) placebo @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
70% (n=30) vs 7.7% (n=26) placebo @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
25% (n=28) vs 7.7% (n=26) placebo @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
76.4% (n=432) vs 3.2% (n=431) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
81.8% (n=433) vs 3.2% (n=431) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
37.4% (n=227) vs 7.5% (n=226) placebo @ 60wkQ12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
72.9% (n=229) vs 7.5% (n=226) placebo @ 60wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
72.9% (n=347) vs 2.4% (n=168) placebo @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
83.2% (n=351) vs 2.4% (n=168) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
80.9% (n=115) vs 10.7% (n=56) placebo @ 12wk
NCT03073200 · Phase 3
47.8% (n=115) vs 7.1% (n=56) placebo @ 4wk
NCT03073200 · Phase 3
76.3% (n=38) vs 5.3% (n=19) placebo @ 12wk
NCT03073200 · Phase 3
65.4% (n=52) vs 17.1% (n=41) placebo @ 24wkQ4W
NCT01695239 · Phase 3
73.2% (n=41) vs 17.1% (n=41) placebo @ 24wkQ2W
NCT01695239 · Phase 3
86.5% (n=52) vs 13.2% (n=53) Fumaric Acid Esters @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
83.6% (n=134) vs 57.2% (n=166) Ustekinumab @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PASI 75 84.2% (n=386) vs 7.3% (n=193) placebo @ 12wk80 mg every 4 weeks
responder rate · % of participants
NCT01646177 · Phase 3 · converted to % from 325 Participants as posted
show 21 more results
87.3% (n=385) vs 7.3% (n=193) placebo @ 12wk*80 mg every 2 weeks
NCT01646177 · Phase 3 · converted to % from 336 Participants as posted
87.4% (n=174) vs 8% (n=88) placebo @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
93.8% (n=176) vs 8% (n=88) placebo @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
82.1% (n=28) vs 7.7% (n=26) placebo @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
82.6% (n=23) vs 0% (n=6) placebo @ 32wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
82.8% (n=29) vs 7.7% (n=26) placebo @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
56.5% (n=23) vs 0% (n=6) placebo @ 32wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
76.7% (n=30) vs 7.7% (n=26) placebo @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
59.1% (n=23) vs 0% (n=6) placebo @ 32wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
28.6% (n=28) vs 7.7% (n=26) placebo @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
50% (n=22) vs 0% (n=6) placebo @ 32wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
82.6% (n=432) vs 3.9% (n=431) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
89.1% (n=433) vs 3.9% (n=431) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
77.5% (n=347) vs 2.4% (n=168) placebo @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
89.7% (n=351) vs 2.4% (n=168) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
88.7% (n=115) vs 25% (n=56) placebo @ 12wk
NCT03073200 · Phase 3
53.9% (n=115) vs 8.9% (n=56) placebo @ 4wk
NCT03073200 · Phase 3
84.2% (n=38) vs 26.3% (n=19) placebo @ 12wk
NCT03073200 · Phase 3
22.9% (n=520) vs 5.1% (n=507) Guselkumab @ 2wk
NCT03573323 · Phase 4 · registry result, not featured evidence
90.7% (n=54) vs 22.2% (n=54) Fumaric Acid Esters @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
88.2% (n=136) vs 68.7% (n=166) Ustekinumab @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
sPGA (0 36% (n=386) vs 0% (n=193) placebo @ 12wk80 mg every 4 weeks
responder rate · % of participants
NCT01646177 · Phase 3 · converted to % from 139 Participants as posted
show 10 more results
40.3% (n=385) vs 0% (n=193) placebo @ 12wk*80 mg every 2 weeks
NCT01646177 · Phase 3 · converted to % from 155 Participants as posted
35.6% (n=174) vs 0% (n=88) placebo @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
36.4% (n=176) vs 0% (n=88) placebo @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
34.5% (n=432) vs 0% (n=431) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
37% (n=433) vs 0% (n=431) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
32.3% (n=347) vs 0.6% (n=168) placebo @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
41.9% (n=351) vs 0.6% (n=168) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
52.2% (n=115) vs 1.8% (n=56) placebo @ 12wk
NCT03073200 · Phase 3
41.9% (n=520) vs 25.2% (n=507) Guselkumab @ 12wk
NCT03573323 · Phase 4 · registry result, not featured evidence
41.9% (n=136) vs 18.1% (n=166) Ustekinumab @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PASI 90 64.6% (n=432) vs 0.5% (n=431) placebo @ 12wkQ4W
responder rate · % of participants
PASI90
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
70.9% (n=433) vs 0.5% (n=431) placebo @ 12wkQ2W
PASI90
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
PASI 100 33.6% (n=432) vs 0% (n=431) placebo @ 12wkQ4W
responder rate · % of participants
PASI100
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
35.3% (n=433) vs 0% (n=431) placebo @ 12wkQ2W
PASI100
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Itch NRS 80.5% (n=379) vs 15.5% (n=374) placebo @ 12wkQ4W
responder rate · % of participants
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
85.9% (n=391) vs 15.5% (n=374) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
DLQI -9.6 vs -1.7 placebo score @ 12wk80 mg every 4 weeks
absolute change · score
NCT01646177 · Phase 3
show 13 more results
-10.2 vs -1.7 placebo score @ 12wk80 mg every 2 weeks
NCT01646177 · Phase 3
-8.6 vs 0.92 placebo score @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
-8.86 vs 0.92 placebo score @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
-8.17 vs -1.24 placebo score @ 16wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-8.39 vs -1.24 placebo score @ 16wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-6.59 vs -1.24 placebo score @ 16wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-6.35 vs -1.24 placebo score @ 16wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-10.7 vs -1 placebo score @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-11.1 vs -1 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-9.4 vs -2 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-10.4 vs -2 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-9.7 vs -1.4 placebo score @ 12wkQ2W
NCT02718898 · Phase 3 · registry result, not featured evidence
-13.08 vs -5.37 Fumaric Acid Esters score @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
NAPSI -9.9793 vs 1.6362 placebo score @ 12wk80 mg every 4 weeks
absolute change · score
NCT01646177 · Phase 3
show 15 more results
-10.4145 vs 1.6362 placebo score @ 12wk80 mg every 2 weeks
NCT01646177 · Phase 3
-11.35 vs -1.26 placebo score @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
-10.07 vs -1.26 placebo score @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
-19.91 vs 2.21 placebo score @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-15.89 vs 2.21 placebo score @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-3.65 vs 2.21 placebo score @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-4.85 vs 2.21 placebo score @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-7.19 vs 2.17 placebo score @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-7.24 vs 2.17 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-7.39 vs -0.82 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-8.6 vs -0.82 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-16.87 vs 0.17 placebo score @ 12wk
NCT03073200 · Phase 3
-14 vs -2.4 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-15.5 vs -2.4 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-12.24 vs -5.02 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
BSA Involvement -23.2% (n=377) vs -0.7% (n=192) placebo @ 12wk80 mg every 4 weeks
absolute value · percentage points
NCT01646177 · Phase 3
show 3 more results
-23.2% (n=380) vs -0.7% (n=192) placebo @ 12wk80 mg every 2 weeks
NCT01646177 · Phase 3
-21.4% (n=425) vs 1.3% (n=426) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-22.4% (n=428) vs 1.3% (n=426) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
PSSI -18.2 vs -5 placebo score @ 12wk80 mg every 4 weeks
absolute change · score
NCT01646177 · Phase 3
show 14 more results
-18.8 vs -5 placebo score @ 12wk80 mg every 2 weeks
NCT01646177 · Phase 3
-18.33 vs -1.59 placebo score @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
-19.52 vs -1.59 placebo score @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
-17.2 vs -7.3 placebo score @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-15 vs -7.3 placebo score @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-15.8 vs -7.3 placebo score @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-10.2 vs -7.3 placebo score @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-18.3 vs -1.8 placebo score @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-19.2 vs -1.8 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-18.5 vs -3.8 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-18.7 vs -3.8 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-27.64 vs -12.28 placebo score @ 12wk
NCT03073200 · Phase 3
-20.85 vs -6.76 Fumaric Acid Esters score @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
-19.29 vs -16 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PatGA -3.1 vs -0.2 placebo score @ 12wkQ4W
absolute change · score
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 7 more results
-3.2 vs -0.2 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-3 vs -0.4 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-3.2 vs -0.4 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-33.8 vs -14.8 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-35.6 vs -14.8 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-3.12 vs -0.87 Fumaric Acid Esters score @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
-3.07 vs -2.6 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PASI 90 65.3% (n=386) vs 3.1% (n=193) placebo @ 12wk80 mg every 4 weeks
responder rate · % of participants
NCT01646177 · Phase 3 · converted to % from 252 Participants as posted
show 10 more results
68.1% (n=385) vs 3.1% (n=193) placebo @ 12wk*80 mg every 2 weeks
NCT01646177 · Phase 3 · converted to % from 262 Participants as posted
75.9% (n=174) vs 2.3% (n=88) placebo @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
82.4% (n=176) vs 2.3% (n=88) placebo @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
59.7% (n=347) vs 0.6% (n=168) placebo @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
70.7% (n=351) vs 0.6% (n=168) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
78.3% (n=115) vs 5.4% (n=56) placebo @ 12wk
NCT03073200 · Phase 3
21% (n=520) vs 7.9% (n=507) Guselkumab @ 4wk
NCT03573323 · Phase 4 · registry result, not featured evidence
58.5% (n=520) vs 35.9% (n=507) Guselkumab @ 8wk
NCT03573323 · Phase 4 · registry result, not featured evidence
79.6% (n=54) vs 9.3% (n=54) Fumaric Acid Esters @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
72.8% (n=136) vs 42.2% (n=166) Ustekinumab @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence

+ 106 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ixekizumab's landscape · vunakizumab's landscape